Molecular Dynamics and CLONTECH Laboratories Agree to Co-Develop and Co-Market Prefabricated cDNA Expression Microarrays

Prefabricated Microarrays to Be Part of Complete System for

Gene Expression Analysis

Sep 14, 1998, 01:00 ET from CLONTECH Laboratories, Inc.

    SUNNYVALE and PALO ALTO, Calif., Sept. 14 /PRNewswire/ -- Molecular
 Dynamics, Inc. and CLONTECH Laboratories, Inc. have signed an agreement to
 jointly develop and market specially prepared microscope slides that are
 prearrayed with up to 10,000 spots of cloned DNA material.  Designed for
 high-throughput research and development environments, the prefabricated
 microarrays will help life scientists measure differential gene expression
 levels quickly and accurately in a number of human and model systems, enabling
 faster identification of therapeutic targets and development of diagnostic
     Under the terms of the collaborative agreement, Molecular Dynamics will
 provide mechanical spotting instrumentation, software support, chemistry
 expertise, and access to key intellectual property.  CLONTECH Laboratories
 will provide sequence-validated cDNAs generated using proprietary
 bioinformatics tools as well as other relevant technology utilized in their
 existing nylon Atlas(TM) cDNA Expression Arrays.  Together the two companies
 will design and produce microarrays using their combined array expertise.
     Plans include the release of gene expression microarrays prespotted with
 cDNAs critical for the study of neurobiology, stress, and cancer and other
 diseases in human and model systems such as mouse and rat.  Each microarray
 will have a set of a few hundred to a few thousand uniquely defined cDNA
 sequences (patents pending) of known genes selected for their importance in
 various critical cellular functions.  Importantly for end users, the
 prefabricated microarrays are licensed under the issued and pending patents of
 Affymetrix through the license agreement between Molecular Dynamics and
 Affymetrix previously announced in December, 1997.  Additionally, the genomic
 content provided by CLONTECH will be covered under the issued PCR patents of
     Integrated Microarray Solutions for Genetic Analysis
     Following initial testing and validation, the prefabricated cDNA
 expression microarrays will be made broadly available to the life sciences
 market through a joint marketing and support program.  Over time, CLONTECH and
 Molecular Dynamics plan to develop and introduce a wide range of microarray
 products that will address an increasing number of life science applications.
     For testing and validation, early versions of these prefabricated
 microarrays will be made available to participants in the Microarray
 Technology Access Program (MTAP), which is jointly sponsored and administered
 by Molecular Dynamics and Amersham Pharmacia Biotech.  MTAP participants will
 enjoy access to a fully integrated microarray platform, including microarray
 fabrication instrumentation, optical scanning instrumentation, optimized
 reagent chemistries for fluorescent detection, software for array quantitation
 and analysis, intellectual property, training and technical support.
     A Collaborative Approach
     The agreement between Molecular Dynamics and CLONTECH is the first of its
 kind to announce plans to develop and produce a broad range of licensed,
 prefabricated cDNA microarrays.  The companies plan to extend their
 collaboration with additional activities in the rapidly growing field of
 functional genomics.
     About the Collaborators
     Headquartered in Palo Alto, California, CLONTECH Laboratories
 ( is a provider of innovative enabling technologies to the
 life sciences research market.  Using their expertise in several areas
 including PCR, genetic reporter systems, RNA technology, gene expression
 systems, and differential gene expression, the Company produces a wide range
 of innovative biological materials, kits, and support products that have
 proven to be highly valuable tools in various fields of life science research
 such as cancer research, neurobiology, pharmacology, cell biology, genomics,
 and functional genomics.  CLONTECH also markets various membrane-based Atlas
 macroarrays drawn from an extensive in-house repository of sequence-validated
 cDNA clones.
     Molecular Dynamics (, based in Sunnyvale, California, is a
 leading developer, manufacturer and international marketer of systems that
 accelerate genetic discovery and analysis.  The Company's products
 dramatically increase scientists' ability to visualize, quantify and analyze
 genetic information.  Molecular Dynamics has been working with Amersham
 Pharmacia Biotech since 1994 to develop integrated systems for genetic
 analysis.  Molecular Dynamics recently announced a merger agreement with
 Amersham Pharmacia Biotech.  Following completion of the merger, Amersham
 Pharmacia Biotech will assume all rights and obligations of Molecular Dynamics
 under this agreement with the full consent of CLONTECH Laboratories.
     Amersham Pharmacia Biotech ( is the world's largest
 supplier of enabling technology to the biotechnology industry, providing a
 wide range of reagents, systems and services focused on genomics research and
 pharmaceutical development.  Headquartered in Uppsala, Sweden, the company has
 combined annual sales of approximately $700 million and employs 3,600
 employees worldwide.
     Except for the historical information contained herein, the matters
 discussed in this news release are forward-looking statements that involve
 risks and uncertainties, including the timely shipment of new products, the
 effect of competitive pressures and other risks detailed from time to time in
 Molecular Dynamics' SEC reports, including the Annual Report on Form 10-K for
 the fiscal year ended December 31, 1997, and the Quarterly Report on Form 10-Q
 for the quarter ended June 30, 1998.

SOURCE CLONTECH Laboratories, Inc.